Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Colorectal Neoplasms 618Pancreatic Neoplasms 377Carcinoma, Hepatocellular 293Stomach Neoplasms 239Rectal Neoplasms 178Colonic Neoplasms 162Carcinoma, Non-Small-Cell Lung 162Esophageal Neoplasms 160Breast Neoplasms 140Neoplasms 130Neoplasm Metastasis 123Ovarian Neoplasms 117Lung Neoplasms 107Cholangiocarcinoma 106Liver Neoplasms 98Gastrointestinal Neoplasms 95Melanoma 84Biliary Tract Neoplasms 75Prostatic Neoplasms 73Endometrial Neoplasms 69Esophageal Squamous Cell Carcinoma 66Carcinoma, Renal Cell 56Sarcoma 54Squamous Cell Carcinoma of Head and Neck 53Uterine Cervical Neoplasms 48Head and Neck Neoplasms 46Adenocarcinoma Of Esophagus 45Urinary Bladder Neoplasms 39Triple Negative Breast Neoplasms 37Gastrointestinal Stromal Tumors 34

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × Gastrointestinal × 90 days × Clear all
NCT04500548 2026-06-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡